General Electric buys Clarient
GENERAL Electric has agreed to buy molecular diagnostic company Clarient for $580m as it looks to accelerate the development of integrated tools for cancer diagnosis and characterisation.
Reuters reported that General Electric Co reported a sharper than expected drop in revenue on slack demand for heavy equipment, casting doubts about the pace of the US recovery from the worst economy since the Great Depression.